Evaluating the potential of relapse-free survival as a surrogate for overall survival in the adjuvant therapy of melanoma with checkpoint inhibitors

Recent changes in the adjuvant treatment of melanoma have raised interest in confirming relapse-free survival (RFS) as a surrogate for overall survival (OS).

Source: European Journal of Cancer - August 6, 2020 Category: Cancer & Oncology Authors: Elisabeth Coart, Stefan Suciu, Pierre Squifflet, Everardo D. Saad, Andriy Moshyk, Gaetan de Schaetzen, Marc Buyse, Jeffrey S. Weber, Alexander Eggermont, Srividya Kotapati Tags: Original Research Source Type: research